• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

螺内酯、坎利酮及其共同代谢产物坎利酮对 Dimension Vista 地高辛检测的影响。

Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista Digoxin Assay.

机构信息

Department of Pathology and Laboratory Medicine, University of Texas-Houston Medical School and Laboratory Services, Memorial-Hermann Hospital at Texas Medical Center, Houston, Texas 77030, USA.

出版信息

J Clin Lab Anal. 2010;24(6):413-7. doi: 10.1002/jcla.20421.

DOI:10.1002/jcla.20421
PMID:21089173
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6647715/
Abstract

Spironolactone, a potassium sparing diuretic metabolized to canrenone, is often used with digoxin to treat various conditions including congestive heart failure. Potassium canrenoate is a similar drug that is also metabolized to canrenone. Due to reported interference of spironolactone, potassium canrenoate, and their common metabolite canrenone with digoxin immunoassays, we investigated potential interference of these compounds with Dimension Vista Digoxin immunoassay using Flex reagent cartridge. Aliquots of a drug-free serum pool were supplemented with various amounts of spironolactone, potassium canrenoate, or canrenone and apparent digoxin values were measured using Dimension Vista digoxin assay, we observed none-detected value except when aliquots were supplemented with higher amounts of spironolactone or canrenone. Similarly, when aliquots of a serum digoxin pool (prepared by pooling specimens from patients receiving digoxin) where further supplemented with various amounts of spironolactone, potassium canrenoate, or canrenone, we observed moderately falsely elevated digoxin values only in specimens containing higher amounts of spironolactone or canrenone. We conclude that spironolactone and canrenone but not potassium canrenoate may cause modest interference with Dimension Vista digoxin assay but such interferences may not be clinically significant except with very high amounts of canrenone.

摘要

螺内酯,一种保钾利尿剂,代谢为坎利酮,常与地高辛一起用于治疗充血性心力衰竭等各种病症。坎利酮酸钾也是一种类似的药物,也代谢为坎利酮。由于报道螺内酯、坎利酮酸钾及其共同代谢产物坎利酮会干扰地高辛免疫测定,我们使用 Flex 试剂卡研究了这些化合物对 Dimension Vista 地高辛免疫测定的潜在干扰。将无药物血清池的等分试样分别补充不同量的螺内酯、坎利酮酸钾或坎利酮,并用 Dimension Vista 地高辛测定法测量表观地高辛值,除了补充高剂量的螺内酯或坎利酮时,我们观察到无检测值。同样,当进一步用不同量的螺内酯、坎利酮酸钾或坎利酮补充从接受地高辛治疗的患者中汇集的血清地高辛池的等分试样时,我们仅在含有高剂量螺内酯或坎利酮的标本中观察到中度假性升高的地高辛值。我们得出结论,螺内酯和坎利酮但不是坎利酮酸钾可能会对地高辛测定法造成适度干扰,但这种干扰可能不具有临床意义,除非坎利酮的含量非常高。

相似文献

1
Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista Digoxin Assay.螺内酯、坎利酮及其共同代谢产物坎利酮对 Dimension Vista 地高辛检测的影响。
J Clin Lab Anal. 2010;24(6):413-7. doi: 10.1002/jcla.20421.
2
Clinically insignificant negative interferences of spironolactone, potassium canrenoate, and their common metabolite canrenone in new dimension vista LOCI digoxin immunoassay.螺内酯、坎利酮及其共同代谢产物坎利酮在新维度 vista LOCI 地高辛免疫分析中对地高辛的临床无显著负干扰。
J Clin Lab Anal. 2012 May;26(3):143-7. doi: 10.1002/jcla.21501.
3
A new turbidometric digoxin immunoassay on the ADVIA 1650 analyzer is free from interference by spironolactone, potassium canrenoate, and their common metabolite canrenone.在ADVIA 1650分析仪上进行的一种新的比浊法地高辛免疫测定不受螺内酯、坎利酸钾及其共同代谢产物坎利酮的干扰。
Ther Drug Monit. 2003 Aug;25(4):478-82. doi: 10.1097/00007691-200308000-00011.
4
Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common metabolite canrenone.雅培 ARCHITECT 临床化学和免疫分析系统:地高辛检测不受螺内酯、坎利酮及其常见代谢产物坎利酮的干扰。
Ther Drug Monit. 2011 Feb;33(1):128-31. doi: 10.1097/FTD.0b013e3181fd4c30.
5
Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.螺内酯、坎利酸钾及其共同代谢产物坎利酮对采用新型地高辛免疫分析法地高辛III测定血清地高辛的影响。
Ther Drug Monit. 2008 Dec;30(6):744-7. doi: 10.1097/FTD.0b013e31818b0e6a.
6
Bidirectional (positive/negative) interference of spironolactone, canrenone, and potassium canrenoate on serum digoxin measurement: elimination of interference by measuring free digoxin or using a chemiluminescent assay for digoxin.螺内酯、坎利酮和坎利酸钾对血清地高辛测量的双向(正向/负向)干扰:通过测量游离地高辛或使用地高辛化学发光测定法消除干扰。
J Clin Lab Anal. 2002;16(4):172-7. doi: 10.1002/jcla.10039.
7
A new enzyme-linked chemiluminescent immunosorbent digoxin assay is virtually free from interference of spironolactone, potassium canrenoate, and their common metabolite canrenone.一种新的酶联化学发光免疫吸附地高辛测定法几乎不受螺内酯、坎利酸钾及其共同代谢产物坎利酮的干扰。
J Clin Lab Anal. 2006;20(5):204-8. doi: 10.1002/jcla.20133.
8
Digoxin assays: frequent, substantial, and potentially dangerous interference by spironolactone, canrenone, and other steroids.地高辛测定:螺内酯、坎利酮及其他甾体类药物频繁、显著且可能具有危险性的干扰作用。
Clin Chem. 2002 Mar;48(3):507-16.
9
Reassessment of cross-reactivity of spironolactone metabolites with four digoxin immunoassays.螺内酯代谢物与四种地高辛免疫测定法交叉反应性的重新评估。
Ther Drug Monit. 1989;11(2):200-4. doi: 10.1097/00007691-198903000-00013.
10
Interference between eplerenone and digoxin in fluorescence polarization immunoassay, microparticle enzyme immunoassay, and affinity column-mediated immunoassay.依普利酮对荧光偏振免疫分析法、微粒子酶免疫分析法和亲和柱介导免疫分析法测定地高辛的干扰。
Ther Drug Monit. 2010 Dec;32(6):774-7. doi: 10.1097/FTD.0b013e3181e649a0.

引用本文的文献

1
Development of a useful single-reference HPLC method for therapeutic drug monitoring of phenytoin and carbamazepine in human plasma.开发一种有用的单参考 HPLC 方法,用于人血浆中苯妥英和卡马西平的治疗药物监测。
Anal Sci. 2023 Apr;39(4):447-454. doi: 10.1007/s44211-023-00266-z. Epub 2023 Jan 13.
2
Clinically insignificant negative interferences of spironolactone, potassium canrenoate, and their common metabolite canrenone in new dimension vista LOCI digoxin immunoassay.螺内酯、坎利酮及其共同代谢产物坎利酮在新维度 vista LOCI 地高辛免疫分析中对地高辛的临床无显著负干扰。
J Clin Lab Anal. 2012 May;26(3):143-7. doi: 10.1002/jcla.21501.

本文引用的文献

1
Therapeutic drug monitoring of digoxin: impact of endogenous and exogenous digoxin-like immunoreactive substances.
Toxicol Rev. 2006;25(4):273-81. doi: 10.2165/00139709-200625040-00007.
2
Digoxin assays: frequent, substantial, and potentially dangerous interference by spironolactone, canrenone, and other steroids.地高辛测定:螺内酯、坎利酮及其他甾体类药物频繁、显著且可能具有危险性的干扰作用。
Clin Chem. 2002 Mar;48(3):507-16.
3
Unexpected suppression of immunoassay results by cross-reactivity: now a demonstrated cause for concern.交叉反应对免疫测定结果的意外抑制:现已证实值得关注。
Clin Chem. 2002 Mar;48(3):405-6.
4
Intoxication due to negative canrenone interference in digoxin drug monitoring.因坎利酮阴性干扰地高辛药物监测导致的中毒
Lancet. 1999 Oct 2;354(9185):1176-7. doi: 10.1016/S0140-6736(99)03818-0.
5
Cross-reactivity of TDX and OPUS immunoassay systems for serum digoxin determination.
Ther Drug Monit. 1997 Dec;19(6):657-62. doi: 10.1097/00007691-199712000-00009.
6
Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man.健康男性口服螺内酯及静脉注射坎利酸钾后坎利酮的药代动力学
Eur J Clin Pharmacol. 1983;25(4):449-53. doi: 10.1007/BF00542109.
7
Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.
J Pharmacol Exp Ther. 1973 Jun;185(3):686-95.
8
Pharmacokinetics of spironolactone and potassium canrenoate in humans.
J Pharmacobiodyn. 1985 Mar;8(3):161-6. doi: 10.1248/bpb1978.8.161.
9
The effect of renal and hepatic impairment and of spironolactone on digoxin immunoassays.
Eur J Clin Pharmacol. 1988;34(3):233-9. doi: 10.1007/BF00540949.
10
Difference in metabolic profile of potassium canrenoate and spironolactone in the rat: mutagenic metabolites unique to potassium canrenoate.
Arch Toxicol. 1988 Jan;61(3):201-12. doi: 10.1007/BF00316635.